<DOC>
	<DOCNO>NCT01730768</DOCNO>
	<brief_summary>This study chronic stable Schizophrenia purpose answer question whether agonism nicotinic alpha7 receptor capable enhance cognition well define chronic stable patient population treat antipsychotic standard care , thus support future development AQW051 treatment cognitive impairment associate Schizophrenia ( CIAS ) .</brief_summary>
	<brief_title>A Study Evaluate Effects Once Daily Doses AQW051 Cognition , Stable Schizophrenia Patients</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Diagnosis schizophrenia Symptomatically stable currently treat stable regimen least 3 ( three ) month prior dose one follow second generation antipsychotic : risperidone , paliperidone , quetiapine , ziprasidone , aripiprazole . Specific cognitive impairment Smokers nonsmoker Current treatment anticholinergic agent know adversely interfere cholinergic system , and/ treatment cholinesterase inhibitor within last three ( 3 ) month prior dose . Current treatment conventional antipsychotic ( e.g fluphenazine , haloperidol ) clozapine . History neuroleptic malignant syndrome . Diagnosis substance abuse ( nicotine ) within last month alcohol substance dependence ( nicotine ) within last 6 month . Score 4 5 Suicidal Ideation item `` yes '' Suicidal Behavior item CSSRS relate suicidal behavior occur last 2 year Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>schizophrenia , chronic stable schizophrenia , cognition , memory , visual learning , CogState</keyword>
</DOC>